Cash flows from operating activities: | |
Net income | |
Adjustments to reconcile net income to net cash (used in) provided by operating activities: | |
Depreciation and amortization | 63.1M |
Amortization of Credit Agreement deferred financing costs | |
Accretion of interest income on short-term investments | |
Deferred income taxes | |
Provision for uncertain tax positions | |
Tax benefit related to the exercise of employee stock options | -507K |
Deferred revenue | |
Deferred product manufacturing costs | |
Recognition of deferred revenue | |
Amortization of deferred product manufacturing costs | |
Accrued profit sharing and royalty expense | |
Payments of profit sharing and royalty expense | |
Payments of accrued litigation settlements | |
Share-based compensation expense | 23.38M |
Bad debt expense | 48.04M |
Changes in certain assets and liabilities: | |
Accounts receivable | 36.82M |
Inventory | -50.52M |
Prepaid expenses and other assets | -42.66M |
Accounts payable, accrued expenses and income taxes payable | |
Other liabilities | 2.28M |
Net cash (used in) provided by operating activities | 97.77M |
Cash flows from investing activities: | |
Purchase of short-term investments | |
Maturities of short-term investments | 0 |
Purchases of property, plant and equipment | -31.86M |
Net cash provided by (used in) investing activities | -604.81M |
Cash flows from financing activities: | |
Tax benefit related to the exercise of employee stock options | 507K |
Proceeds from exercise of stock options and ESPP | |
Net cash provided by financing activities | 397.78M |
Net increase in cash and cash equivalents | -108.23M |
Cash and cash equivalents, beginning of period | 340.35M |
Cash and cash equivalents, end of period | 232.12M |
Supplemental disclosure of non-cash investing and financing activities: | |
Cash paid for interest | 8.21M |
Cash paid for income taxes |